Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development

Eric A. Wold, Christopher T. Wild, Kathryn A. Cunningham, Jia Zhou

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDAapproved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2CR, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.

Original languageEnglish (US)
Pages (from-to)1381-1398
Number of pages18
JournalCurrent topics in medicinal chemistry
Volume19
Issue number16
DOIs
StatePublished - Jan 1 2019

Fingerprint

Receptor, Serotonin, 5-HT2C
Ligands
Serotonin
Obesity
Artificial Receptors
Serotonin 5-HT2 Receptor Agonists
Disruptive, Impulse Control, and Conduct Disorders
Drug Discovery
G-Protein-Coupled Receptors
Substance-Related Disorders
Schizophrenia
Anxiety
Central Nervous System
Depression

Keywords

  • 5-HT2C receptor
  • Agonists
  • Allosteric modulation
  • Central nervous system disorders
  • Drug discovery
  • Ligand development
  • Neurotherapeutics
  • Pharmacological probes
  • Positive allosteric modulators
  • Signaling bias
  • Target selectivity.

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development. / Wold, Eric A.; Wild, Christopher T.; Cunningham, Kathryn A.; Zhou, Jia.

In: Current topics in medicinal chemistry, Vol. 19, No. 16, 01.01.2019, p. 1381-1398.

Research output: Contribution to journalReview article

@article{6ba05e4c307548a5bf9d50c139b4193e,
title = "Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development",
abstract = "Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDAapproved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2CR, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.",
keywords = "5-HT2C receptor, Agonists, Allosteric modulation, Central nervous system disorders, Drug discovery, Ligand development, Neurotherapeutics, Pharmacological probes, Positive allosteric modulators, Signaling bias, Target selectivity.",
author = "Wold, {Eric A.} and Wild, {Christopher T.} and Cunningham, {Kathryn A.} and Jia Zhou",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1568026619666190709101449",
language = "English (US)",
volume = "19",
pages = "1381--1398",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "16",

}

TY - JOUR

T1 - Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development

AU - Wold, Eric A.

AU - Wild, Christopher T.

AU - Cunningham, Kathryn A.

AU - Zhou, Jia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDAapproved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2CR, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.

AB - Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDAapproved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2CR, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.

KW - 5-HT2C receptor

KW - Agonists

KW - Allosteric modulation

KW - Central nervous system disorders

KW - Drug discovery

KW - Ligand development

KW - Neurotherapeutics

KW - Pharmacological probes

KW - Positive allosteric modulators

KW - Signaling bias

KW - Target selectivity.

UR - http://www.scopus.com/inward/record.url?scp=85072628925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072628925&partnerID=8YFLogxK

U2 - 10.2174/1568026619666190709101449

DO - 10.2174/1568026619666190709101449

M3 - Review article

C2 - 31288724

AN - SCOPUS:85072628925

VL - 19

SP - 1381

EP - 1398

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 16

ER -